Reuters Cites Statement From Sarepta Therapeutics Saying 51-Year-Old Male Patient Died In An Early Stage Study Of Co's Therapy SRP-9004; Patient Was The Last To Be Dosed In The Study, And Died Of Acute Liver Failure; Prioritized Disclosing Trial P...

+3.34%

Sarepta Therapeutics, Inc.

SRPT

22.27

+3.34%

Reuters Cites Statement From Sarepta Therapeutics Saying 51-Year-Old Male Patient Died In An Early Stage Study Of Co's Therapy SRP-9004; Patient Was The Last To Be Dosed In The Study, And Died Of Acute Liver Failure; Prioritized Disclosing Trial Patient Death To Clinicians, Regulators In Accordance With Trial Guidelines; Acute Liver Failure Is Not A New Safety Signal, Occurred In A Trial For A Program That Co Is Not Moving Forward With

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.